NEW YORK (GenomeWeb News) – Helicos BioSciences cut its second-quarter net loss significantly on lower R&D and SG&A costs, according to the firm's quarterly filing with the US Securities and Exchange Commission.

The Cambridge, Mass.-based firm reported total revenues of $371,000 for the three-month period ended June 30, up from $251,000 for the second quarter of 2008. It said that $213,000 of its revenues in Q2 2009 came from a government research grant, while $158,000 came from product revenue, which primarily consisted of reagent sales.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.